OnKure Therapeutics, Inc.
OKURHealthcare|Biotechnology|US
$2.87
+0.34 (+13.47%)
DCF Value
$4.23
Tangible Book / Share
$3.16
Cash / Share
$3.27
About
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Stock Price
-9.2%(1Y)
1M
+24.6%
3M
-30.8%
6M
-26.7%
YTD
-1.2%
1Y
-6.7%
3Y
-95.9%
5Y
-96.6%
Pipeline Summary
9 total trials6
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
Completed: 6Active: 1Terminated: 2
Active Trials (1)
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer
Phase 1Active
Enrollment: 200 participants
Key Facts
Market Cap$116.0M
Employees45 (-2% YoY)
CEONicholas A. Saccomano
IPO DateApr 8, 2021
Beta0.30
52-Week Range$2.01 – $5.38
Avg Volume253,694
ExchangeNASDAQ
Websiteonkuretherapeutics.com
Ownership
Float68.7%
Shares Outstanding40.5M
Recent Insider Trades
Saccomano Nicholas ASELL
Sep 21, 202687 shares @ $2.97
Leverone Jason A.SELL
Sep 21, 2026302 shares @ $2.97
Manke IsaacOTHER
Aug 7, 20260 shares
Mathers Edward TAWARD
Aug 7, 202622,350 shares @ $4.14
Ratcliffe LiamAWARD
Aug 7, 202622,350 shares @ $4.14
Peers
Recent News
OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Nov 4, 2026 · globenewswire.com
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
Aug 31, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:26 AM